128 related articles for article (PubMed ID: 36420610)
1. NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway.
Yu W; He J; Wang F; He Q; Shi Y; Tao X; Sun B
Immunology; 2023 May; 169(1):69-82. PubMed ID: 36420610
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cell-Derived Interferon-Gamma Promotes Hepatocellular Carcinoma Through the Epithelial Cell Adhesion Molecule-Epithelial-to-Mesenchymal Transition Axis in Hepatitis B Virus Transgenic Mice.
Chen Y; Hao X; Sun R; Wei H; Tian Z
Hepatology; 2019 Apr; 69(4):1735-1750. PubMed ID: 30329167
[TBL] [Abstract][Full Text] [Related]
3. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
[TBL] [Abstract][Full Text] [Related]
4. A Regulation Loop between YAP and NR4A1 Balances Cell Proliferation and Apoptosis.
He L; Yuan L; Yu W; Sun Y; Jiang D; Wang X; Feng X; Wang Z; Xu J; Yang R; Zhang W; Feng H; Chen HZ; Zeng YA; Hui L; Wu Q; Zhang Y; Zhang L
Cell Rep; 2020 Oct; 33(3):108284. PubMed ID: 33086070
[TBL] [Abstract][Full Text] [Related]
5. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract][Full Text] [Related]
6. Blocking CD47 promotes antitumour immunity through CD103
Wang S; Wu Q; Chen T; Su R; Pan C; Qian J; Huang H; Yin S; Xie H; Zhou L; Zheng S
J Hepatol; 2022 Aug; 77(2):467-478. PubMed ID: 35367532
[TBL] [Abstract][Full Text] [Related]
7. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
8. STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients.
Huang X; Mo Q; Fu T; Liu Y; Diao B
Immunobiology; 2022 Nov; 227(6):152272. PubMed ID: 36122437
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.
Han J; Ke C; Jiang B; Zhou H; Xu H; Xie X
Clin Exp Immunol; 2021 Dec; 206(3):366-377. PubMed ID: 34562314
[TBL] [Abstract][Full Text] [Related]
10. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
[TBL] [Abstract][Full Text] [Related]
11. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
12. m
Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
[TBL] [Abstract][Full Text] [Related]
13. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway.
Jin Y; Sun Z; Geng J; Yang L; Song Z; Song H; Wang J; Tang J
Int Immunopharmacol; 2019 May; 70():1-8. PubMed ID: 30780004
[TBL] [Abstract][Full Text] [Related]
14. HCV core protein promotes hepatocyte proliferation and chemoresistance by inhibiting NR4A1.
Tan Y; Li Y
Biochem Biophys Res Commun; 2015 Oct; 466(3):592-8. PubMed ID: 26392314
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
17. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
18. Liver-infiltrating CD11b
Zhang QF; Yin WW; Xia Y; Yi YY; He QF; Wang X; Ren H; Zhang DZ
Cell Mol Immunol; 2017 Oct; 14(10):819-829. PubMed ID: 27321064
[TBL] [Abstract][Full Text] [Related]
19. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
Chew V; Tow C; Huang C; Bard-Chapeau E; Copeland NG; Jenkins NA; Weber A; Lim KH; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
J Natl Cancer Inst; 2012 Dec; 104(23):1796-807. PubMed ID: 23197495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
